A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Inclusion Criteria: * Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed having exhausted all appropriate lines of therapy or have no other standard therapy with proven clinical benefit. In Part C, HNSCC participants may enroll as first-line therapy. Exclusion Criteria: * Active of uncontrolled CNS metastasesBrain metastases * History of solid tumors other than the diseases under studyPrior malignancy * History of and/or current cardiovascular events or conditions in the previous 6 monthsCardiac * Pre-existing >/= Grade 2 neuropathy * Hemoglobin A1C (HbA1C) >/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathyDiabetes * Active ocular disease at baseline * Chronic severe liver disease or live cirrhosisHepatic * Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study * Other significant cormorbidities.